EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.
- 46 WiSE implants completed in Q2 2026
- 17 new purchasing contracts signed, total 52
- 90 physicians trained across 30 activated sites
- Preliminary revenue guidance of US$2.5M to US$2.6M
- CMS initiates Medicare coverage review process
Steady Implant Growth and Commercial Focus
EBR Systems (ASX:EBR) marked another quarter of progress for its WiSE wireless cardiac pacing system, completing 46 commercial implants in Q2 2026. This brought total implants across the pilot and Limited Market Release phases to 117, including 87 so far in 2026, reflecting a steady build in clinical adoption. The company is now prioritising deeper utilisation within its existing activated accounts rather than expanding new sites, with more than half of these hospitals having performed three or more WiSE implants.
Contract Expansion and Physician Training
During the quarter, EBR signed 17 new purchasing contracts, lifting the total to 52. Physician training also accelerated, with 26 new specialists trained, bringing the cumulative total to 90 across 30 activated sites. This growing base of trained clinicians underpins the company’s strategy to drive repeat procedures and build operational expertise at existing hospitals, supporting a more sustainable commercial rollout.
Preliminary Revenue and Funding Update
EBR expects to report preliminary Q2 revenue between US$2.50 million and US$2.60 million, subject to final audit adjustments. This comes alongside the near completion of a fully underwritten A$150 million capital raise, with the final A$35 million tranche due by late August. The fresh funding aims to support the company’s push toward cashflow breakeven, expand sales and marketing efforts, scale manufacturing, reduce costs, and continue research and development initiatives.
Regulatory Milestones and Purchasing Agreements
EBR achieved a key regulatory milestone as the US Centers for Medicare & Medicaid Services (CMS) formally initiated the National Coverage Determination (NCD) process for the WiSE system. This step is critical for broader Medicare reimbursement and patient access. Additionally, the company secured purchasing agreements with major healthcare networks including HCA Healthcare, Advocate Health, and CHRISTUS Health, paving the way for wider hospital adoption as the US commercial rollout advances.
Investor Engagement and Clinical Validation
The company maintained active investor and industry engagement, highlighted by participation in the Heart Rhythm 2026 meeting in Chicago. There, Dr Niraj Varma from the Cleveland Clinic presented real-world outcomes showing a halving of complication rates compared to earlier studies, a promising sign for WiSE’s clinical profile. Following the recent capital raise, EBR also conducted media and investor briefings to reinforce its strengthened financial position and ongoing commercial momentum.
Bottom Line?
EBR’s shift to intensify usage within existing accounts while securing key contracts and reimbursement pathways signals a maturing commercial rollout, but upcoming CMS coverage decisions and audited financials will be pivotal for sustained growth.
Questions in the middle?
- How quickly will CMS’s National Coverage Determination translate into broader Medicare reimbursement?
- Will deeper utilisation within existing sites drive a meaningful acceleration in implant volumes?
- How will EBR manage operational scale-up challenges amid expanding commercial demand?